Asymmetric Healthcare Portfolio: up 1.46% in July 2025! 📈
The pharmaceutical sector faced headwinds in July as political pressure from Trump's drug pricing ultimatum and broader market volatility weighed on most pharma stocks, creating a challenging environment for the industry overall.
Despite of the industry wide challenges, Asymmetric Healthcare Portfolio delivered a 1.46% gain in July and a total 5.22% increase in value since the portfolio launch back in the mid of May 2025. 📈
Portfolio page is updated with the details. 🗂️
I have my skin in the game, this portfolio is not a model portfolio. Paid subscribers are able to see proof of transactions.
Below is a detailed update about each equity in the portfolio. 📝
Genmab (GMAB): quietly crushing it
Genmab's price jumped 4.88% in July to close at $21.67.
It's about time.
This stock has been through the wringer over the past year, down 24% while the company kept delivering solid results. Sometimes the market just doesn't make sense.
At a $13.6 billion market cap and 1.08x (!) Owner Earning, GMAB is looking pretty attractive for a biotech that's got both steady royalty checks and a pipeline full of potential blockbusters. The quiet trading volume tells me smart money is positioning ahead of the August 7 earnings call. That's when things could get interesting.
💰 The DARZALEX money printer is busy working
The beautiful thing about Genmab's business model is that every quarter, Johnson & Johnson writes them a royalty check based on DARZALEX sales.
In Q2 that check got bigger: $3.54 billion in worldwide sales, up from $3.24 billion last quarter.
So Genmab's getting paid while they sleep. This isn't some speculative biotech burning cash and praying for FDA approval.
They've got a proven cancer drug generating serious revenue, giving them the luxury to take bigger swings with their pipeline.
🎯 Smart moves behind the scenes
While everyone's focused on the flashy stuff, Genmab's been making some savvy moves:
Share buybacks: they scooped up 2.2 million shares by late June. When a company's buying back stock, they're basically saying "our shares are undervalued and we're putting our money where our mouth is."
Leadership refresh: New legal chief Greg Mueller stepped in after their longtime CLO retired. Smooth transition, no drama, exactly what you want to see.
U.S. expansion: New Jersey hub opening up. Smart play to get closer to the FDA and the world's biggest healthcare market.
🔬 The pipeline that could change everything
Now here's where it gets exciting. Their EPCORE NHL-2 trial just dropped some jaw-dropping numbers:
87% overall response rate
65% complete response rate
For context, these patients had a blood cancer that's notoriously hard to treat. When you're hitting response rates like that, oncologists start paying attention. Real attention.
This isn't just about one drug.
Genmab's becoming a bispecific antibody powerhouse and that's a technology platform that could spawn multiple blockbusters.
📈 Wall Street's waking up
The analyst community is finally catching on:
Truist: raised price target (they see the revenue potential)
Zacks: upgraded to "Strong Buy" (they're not messing around)
UBS: sticking with "Buy" (consistency matters)
Average price target: $30.71
That's 40% upside from current levels…
🎪 Why this matters more than you think
Here's what most people miss about Genmab: they've cracked the code on sustainable biotech success.
The Formula:
Steady cash flow from DARZALEX royalties (no more praying for the next funding round)
Proven platform technology in bispecific antibodies (not just one-hit wonders)
Multiple shots on goal with their pipeline (diversified risk)
Smart capital allocation (buybacks when undervalued, expansion when it makes sense)
This is not the typical "bet the farm on one drug" biotech story.
This is a mature, profitable company that happens to be in the business of curing cancer.
🔮 The August 7 catalyst
Mark your calendars. The Q2 earnings call could be the moment this stock breaks out of its funk.
What I'm watching for:
DARZALEX royalty growth (the cash cow keeps growing)
Pipeline updates (any new clinical data could move the needle)
2025 guidance (management's confidence level)
Capital allocation plans (more buybacks? Strategic acquisitions?)
🎯 The bottom line
While everyone's chasing the next meme biotech, Genmab's been quietly building something special. They've got the rare combination of steady income and explosive upside potential.
This is what sustainable biotech success looks like. Not flashy, not hyped, just solid execution and real results.
Multiple pipeline shots, proven technology platform and analyst price targets suggesting 40% upside.
Those DARZALEX royalties aren't going anywhere and they keep growing.
Most Danish pharmaceutical exports (including Genmab's products) don't actually cross Danish borders for manufacturing. Instead, they use a "merchanting and processing" system where:
the intellectual property stays in Denmark
manufacturing happens in other countries
products ship directly to end markets
Translation: Only 3% of Denmark's total pharmaceutical exports actually pass through Danish customs, meaning Trump's tariffs would have minimal direct impact on Danish companies like Genmab.
Furthermore, Trump is going after the companies that actually control pricing, not the royalty collectors. Because Genmab doesn't set US drug prices, they are not on the list of Trump’s hit list.
I am increasingly bullish.
Merck (MRK): the race against time
Merck has captured significant attention recently and the reasons are compelling. The pharmaceutical giant is successfully managing current market pressures while executing strategic initiatives that could define its next decade. Despite some volatility, MRK shares have demonstrated relative resilience compared to broader healthcare sector performance
🎯 The regulatory victory lap that's actually building a fortress
While most companies celebrate FDA approvals with press releases, Merck is quietly weaponizing their regulatory wins:
The recent events:
KEYTRUDA just scored head and neck cancer approval (expanding their oncology empire)
ENFLONSIA approved for RSV prevention in infants (diversifying beyond cancer)
Multiple Japan approvals (because global domination requires global approvals)
What Wall Street is missing: these are not just approvals, they are building an unbreachable moat. With 25+ cancer types now in their ASCO (American Society Of Clinical Oncology) presentation, Merck is redefining what oncology leadership looks like.
Every new indication extends their competitive advantage and makes it exponentially harder for competitors to catch up. You can't just develop one cancer drug anymore, you need a platform for that.
Merck has the platform.
⚡ Trump's 60-day ultimatum: the plot twist nobody saw coming
Just when you thought pharmaceutical companies had enough to worry about, Trump dropped a bombshell: 60 days to slash drug prices or face "every tool in our arsenal."
The reality check: Merck has diversified portfolio and international presence might actually be their secret weapon. Yes, there will be impact, but this is not an existential crisis.
💰 The $10 Billion Verona bet: genius or desperation?
Spending $10 billion on a respiratory company when you're the oncology king sounds crazy. Until you realize it's absolutely brilliant.
Why this move is pure strategic gold:
COPD (Chronic Obstructive Pulmonary Disease) market: massive, underserved and desperate for innovation
Ohtuvayre (Verona’s medicine): first novel inhaled COPD mechanism in 20 years (that is not incremental, that is revolutionary)
Timing: acquiring before competitors realize respiratory is the next big thing
Diversification: reducing Keytruda dependence while the drug is still printing money
The Alzheimer's Wildcard: they are also doubling down on Alzheimer's research. High risk? Absolutely. High reward? Potentially game-changing. Sometimes you have to swing for the fences.
📊 Q2 Results
Revenue down 2%..
🔥 The Winners:
KEYTRUDA: $8.0 billion (up 9%) - still the undisputed champion
WINREVAIR: $336 million vs. $70 million last year - 380% growth (this is what explosive uptake looks like)
Animal Health: $1.6 billion (up 11%) - proving diversification works
💔 The Loser:
GARDASIL: crashed 55% to $1.1 billion due to China issues - Single-handedly offset Keytruda's growth
Despite revenue declining, non-GAAP EPS beat estimates ($2.13 vs. $2.01 expected).
Gross Margin Improved: 77.5% vs. 76.8% last year, helped by favorable product mix
R&D Spending Up: $4.0 billion (16% increase) including a $200 million upfront payment to Hengrui Pharma
Quantified the tariff damage: $200 million in additional costs for 2025.
Merck's Q2 2025 results showed the company successfully managing through a period of strategic transformation. While revenue declined modestly due to specific product challenges, earnings performance exceeded analyst expectations and management expressed confidence in full-year prospects through raised guidance.
The dividend policy remains robust, providing consistent returns to shareholders even as the company invests heavily in future growth initiatives. This balance between current shareholder returns and long-term investment demonstrates disciplined capital allocation.
🎪 The $3 billion cost optimization
The uncomfortable truth: Merck is cutting $3 billion in costs and reducing workforce.
Why this matters:
patent cliff preparation: getting lean before Keytruda faces generic competition
investment fuel: every dollar saved can be reinvested in R&D and acquisitions
competitive positioning: Lower cost structure = better margins = more flexibility
🌟 The dividend that keeps paying
While cutting costs and facing political pressure, Merck's dividend remains rock-solid. That's the mark of a company that knows how to balance short-term pain with long-term sustainability.
The message: We're confident enough in our future to keep paying shareholders while we transform the business. In my opinion that is not desperation, but calculated confidence.
📈 July's market reality check: when good news meets bad timing
While Merck was executing their strategic transformation flawlessly, the stock closed the month essentially flatc(-1.31%) as investors remained skeptical about the company's ability to navigate the perfect storm of patent cliffs, political pressure and massive capital allocation decisions.
🎯 The investment thesis
What everyone sees: A pharmaceutical company facing patent cliffs and political pressure
What I see is a company with:
$8 billion annual cash flow from Keytruda (for now)
diversification strategy already showing results (WINREVAIR, Animal Health)
cost optimization creating operational leverage
strategic acquisitions positioning for the next decade
regulatory momentum building competitive moats
The conventional wisdom: Keytruda's patent expiration in 2028 is a disaster waiting to happen
The contrarian view: it's the best thing that could happen to Merck's stock price.
Because by 2028:
Verona's respiratory portfolio will be hitting its stride
cost optimization will have created a leaner, more efficient company
new oncology indications will have extended Keytruda's effective life
the market will finally appreciate their transformation
💡 My take: this is not just survival, it is evolution
Merck is orchestrating one of the most ambitious pharmaceutical transformations in recent memory.
The $10 billion Verona acquisition, $3 billion cost program and regulatory momentum aren't separate strategies.
They are coordinated moves in a chess game .
This volatility is creating an opportunity to own a piece of a company that's positioning itself to dominate the next decade of pharmaceutical innovation.
The dividend yield, strong cash flow and proven management track record provide downside protection while the transformation plays out.
The clock is ticking, but this time, it could be ticking in Merck's favor.
💉 Halozyme (HALO): the needle-free revolution that is printing money
HALO is the new addition to our Aysmmetric Healthcare portfolio.
HALO shares climbed 15% in July (although we could not enjoy the full benefit as it was added to the portfolio on 21 July),.
This was pure, sustainable business momentum finally getting recognized. After a sleepy June, the market suddenly woke up to what Halozyme has been building: the ultimate pharma toll road.
While other biotechs are burning cash and praying for FDA approval, Halozyme sits back and collects royalty checks every time a partner sells an ENHANZE-enabled drug. It's like owning a piece of every successful drug launch without the development risk.
💰 When your friends make you rich
The month's biggest catalyst was that Roche and Bristol Myers both dropped stellar sales numbers for their ENHANZE-enabled drugs and every extra vial sold means more royalty cash flowing straight to Halozyme's bottom line.
The beautiful math:
Partner sells more drug → Halozyme gets bigger royalty check
no additional R&D costs for Halozyme
no manufacturing headaches
just pure, scalable profit
Analysts started to raise estimates for 2025.
When analysts start raising numbers, stocks start moving. Simple as that.
🛡️ The patent "drama"
The FUD (Fear, Uncertainty, Doubt): some investors got spooked by whispers of potential patent challenges to ENHANZE's core IP.
The reality check: Halozyme's management came out saying "bring it on" with their patent confidence. And honestly? They should be confident.
Why I think the patent fears are overblown:
ENHANZE has multiple layers of IP protection
The technology is complex and hard to replicate
Halozyme has been building this moat for over a decade
Patent challenges are expensive and time-consuming
My Take: every successful platform eventually faces patent speculation. The fact that competitors might be worried enough to challenge actually validates how valuable ENHANZE has become.
🔬 The pipeline that could change everything
The next level play: Halozyme isn't just sitting on their ENHANZE success, they're aggressively expanding into new drug classes.
What is coming:
Diabetes drugs (massive market, perfect fit for subcutaneous delivery)
Oncology expansion (more cancer drugs going needle-free)
New partnerships (every deal adds to the royalty stream)
The multiplier effect: besides adding revenue, each new drug class validates the platform and makes the next partnership easier to land. This is how you build a pharmaceutical empire.
July's 15% gain wasn't a lucky month.
It was the market finally recognizing that Halozyme has built something genuinely special.
🔮 The second half setup: why this story gets Better
The catalysts ahead:
new partnership announcements (each one adds to the royalty base)
partner drug launches (more products = more revenue)
pipeline updates (expanding into new therapeutic areas)
continued share buybacks (shrinking share count amplifies growth)
🎯 My take
Halozyme built a diversified royalty empire that gets stronger with every partner success.
In a sector full of binary outcomes and cash-burning hopefuls, why wouldn't you want to own the company that gets paid every time everyone else succeeds?
July was just the warm-up act. The main show is what happens when this royalty machine really hits its stride.